Recurrent Disease
21
2
3
11
Key Insights
Highlights
Success Rate
73% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
19.0%
4 terminated out of 21 trials
73.3%
-13.2% vs benchmark
0%
0 trials in Phase 3/4
64%
7 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (21)
Stepped-Care Telehealth for Distress in Cancer Survivors
Pilot Trial for Treatment of Recurrent Glioblastoma
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Safety of Omitting Axillary Surgery in Breast Cancer Patients With Isolated Chest Wall Recurrence
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
Efficacy of SU 011248 in Head And Neck Carcinoma
Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
Proton Beam Re-Irradiation in Thoracic Cancers
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase